Soft Tissue Sarcoma  >>  Halaven (eribulin mesylate)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Halaven (eribulin mesylate) / Eisai
NCT00413192 / 2005-004272-20: E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

Completed
2
128
Europe
E7389
Eisai Inc.
Soft Tissue Sarcoma
06/12
02/13
NCT01458249: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)

Completed
2
52
Japan
eribulin mesylate, E7389
Eisai Co., Ltd.
Soft Tissue Sarcoma
11/14
02/16

Download Options